Nomenclature Evolution: From NAFLD to MASLD

In 2023–2024, an international multi-society Delphi consensus (AASLD, EASL, ALEH, ESPGHAN, and NASPGHAN) replaced "Non-Alcoholic Fatty Liver Disease" (NAFLD) with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Rationale for Nomenclature Shift

  1. Elimination of Stigmatizing Language: The terms "non-alcoholic" and "fatty" carried pejorative connotations for pediatric patients and families.
  2. Affirmative Diagnostic Criteria: NAFLD was an exclusionary diagnosis requiring the absence of alcohol; MASLD is an affirmative diagnosis based on documented cardiometabolic risk factors.
  3. Harmonized Sub-classifications:
    • Steatotic Liver Disease (SLD): Overarching umbrella category for all hepatic steatosis.
    • MASLD: Hepatic steatosis with at least one cardiometabolic risk factor and no other identifiable cause.
    • MASH: Metabolic Dysfunction-Associated Steatohepatitis (formerly NASH), indicating inflammation and hepatocyte ballooning.
    • MetALD: MASLD combined with increased alcohol intake (relevant in older adolescents).
    • Specific Etiology SLDs: Lysosomal acid lipase deficiency (LAL-D), Wilson disease, cystic fibrosis, glycogen storage diseases.

Diagnostic Criteria in Children

1. The Core Definition

Diagnosis requires the objective demonstration of hepatic steatosis (via ultrasound, MRI-PDFF, FibroScan CAP, or liver biopsy) PLUS at least one of the following five cardiometabolic risk factors:

Cardiometabolic Risk DomainPediatric Threshold / Cutoff Criteria
1. Body Mass Index / Adiposity$\text{BMI} \ge 85^{\text{th}}$ percentile for age and sex (overweight/obesity), or waist circumference $>95^{\text{th}}$ percentile
2. Glycemic DysregulationFasting plasma glucose $\ge 100\text{ mg/dL}$ ($5.6\text{ mmol/L}$), or 2-hour OGTT $\ge 140\text{ mg/dL}$ ($7.8\text{ mmol/L}$), or $\text{HbA1c} \ge 5.7\%$, or diagnosed Type 2 Diabetes
3. Blood PressureSystolic or diastolic $\text{BP} \ge 90^{\text{th}}$ percentile for age, sex, and height (or $\ge 130/85\text{ mmHg}$ in youth $\ge 13$ years)
4. Plasma TriglyceridesTriglycerides $\ge 100\text{ mg/dL}$ (in children $<10$ years) or $\ge 130\text{ mg/dL}$ (in children $\ge 10$ years)
5. High-Density Lipoprotein (HDL-C)Serum $\text{HDL-C} \le 40\text{ mg/dL}$ ($1.0\text{ mmol/L}$) across all pediatric age groups

Screening and Staging Protocols

flowchart TD
    A["Target Children for Screening<br/>• All children with BMI ≥ 95th percentile (Age 9–10 yr)<br/>• Children with BMI 85–94th percentile + Cardiometabolic Risk Factors<br/>• Family history of severe MASH or Cirrhosis"] --> B["First-Line Screening Test:<br/>Serum ALT (Sex-Specific Cutoffs)"]
    
    B --> C{"Serum ALT Elevation?<br/>Boys: > 26 U/L | Girls: > 22 U/L"}
    
    C -->|Normal ALT| D["Repeat ALT Screening every 1–2 years if weight remains elevated"]
    C -->|Elevated ALT| E["Persistently elevated > 3 months?<br/>Exclude Wilson disease, viral hepatitis, autoimmune hepatitis, celiac"]
    
    E --> F["Non-Invasive Staging:<br/>Abdominal Ultrasound + Transient Elastography (FibroScan)"]
    
    F --> G{"Stiffness Measurement (LSM)"}
    G -->|"< 6.0 kPa"| H["Low Risk of Advanced Fibrosis<br/>Initiate Structured Lifestyle Modification (IHBLT)"]
    G -->|"6.0–8.5 kPa"| I["Intermediate Risk: Monitor ALT and ELF Score closely"]
    G -->|"> 8.5 kPa"| J["High Risk of Advanced Fibrosis / MASH<br/>Refer to Pediatric Hepatologist for consideration of Liver Biopsy"]

2. Specific Serum ALT Screening Cutoffs

Standard hospital laboratory reference intervals (often listing upper limits of normal up to $45–60\text{ U/L}$) misdiagnose pediatric MASLD. Clinical guidelines mandate using strict pediatric sex-specific cutoffs derived from the NHANES cohort:

  • Boys: $\text{ALT} > 26\text{ U/L}$
  • Girls: $\text{ALT} > 22\text{ U/L}$
  • If ALT is elevated, recheck in 3 months. Persistent elevation requires full secondary etiology workup (Ceruloplasmin, anti-tTG IgA, ANA/SMA/anti-LKM1, HBsAg, anti-HCV).

Non-Invasive Biomarkers and Imaging Staging

Diagnostic ModalityMetric / Cutoff ValueClinical Utility & Limitations
Abdominal UltrasoundQualitative hyperechogenicity ("bright liver")Readily available; insensitive when hepatic steatosis is $<20–30\%$; cannot quantify fibrosis.
Transient Elastography (FibroScan - CAP)Controlled Attenuation Parameter (CAP):
Steatosis: $> 240\text{ dB/m}$ (S1), $> 280\text{ dB/m}$ (S3)
Quantifies fat infiltration accurately without operator dependence.
Liver Stiffness Measurement (LSM - FibroScan)$< 6.0\text{ kPa}$ (F0–F1: No/mild fibrosis)
$6.0–8.5\text{ kPa}$ (F2: Moderate fibrosis)
$> 8.5\text{ kPa}$ (F3–F4: Advanced fibrosis)
High negative predictive value ($>90\%$) to rule out advanced hepatic fibrosis and cirrhosis.
MRI-PDFF (Proton Density Fat Fraction)$\text{PDFF} \ge 5\%$ denotes hepatic steatosisCurrent non-invasive gold standard for quantitative steatosis; expensive, limited availability.
Enhanced Liver Fibrosis (ELF) ScoreProprietary serum panel: HA + PIIINP + TIMP-1Validated in pediatrics; score $>9.8$ correlates with advanced fibrosis.

Management and Therapeutic Evidence

1. Lifestyle Modification (First-Line Therapy)

  • Weight Reduction: A $7–10\%$ reduction in body weight produces marked histological clearance of steatosis and reversal of hepatocyte ballooning.
  • Dietary Specifics: Complete elimination of high-fructose corn syrup and sugar-sweetened beverages (fructose promotes direct hepatic de novo lipogenesis, bypassing phosphofructokinase regulation). Mediterranean-style diet rich in fiber, omega-3 fatty acids, and low glycemic index carbohydrates.
  • Physical Activity: Minimum $\ge 60\text{ minutes/day}$ of moderate-to-vigorous physical activity; reduction in non-educational screen time to $<2\text{ hours/day}$.

2. Pharmacological Evidence

AgentMechanismTrial Evidence & Clinical Recommendation
Vitamin E (RRR-$\alpha$-tocopherol)Potent antioxidant counteracting lipid peroxidation in hepatocytesTONIC Trial ($800\text{ IU/day}$ orally): Demonstrated significant resolution of non-alcoholic steatohepatitis (MASH) and reduction in hepatocyte ballooning in pediatric patients with biopsy-confirmed disease. Recommended for non-diabetic children with biopsy-proven MASH.
GLP-1 Receptor Agonists (Semaglutide, Liraglutide)Centrally induces weight loss, reduces insulin resistance, decreases hepatic lipid contentValidated in adolescents aged $\ge 12$ years with obesity; achieves significant ALT normalization and reduction in liver fat fraction on MRI-PDFF.
MetforminBiguanide insulin sensitizerExtensively evaluated in the TONIC trial; improves systemic insulin resistance and peripheral glycemic control, but fails to improve liver histology or fibrosis. Not recommended specifically for MASH treatment.
Resmetirom (THR-$\beta$ Agonist)Selective thyroid hormone receptor-$\beta$ agonist; increases hepatic fatty acid $\beta$-oxidationApproved for adults with non-cirrhotic MASH with moderate-to-severe fibrosis (MAESTRO-NASH trial); currently undergoing adolescent clinical trials.